Management and outcomes of ruptured, perforated or fistulized tumors of mesenchymal origin. Issue 3 (17th December 2019)

• Record Type: Journal Article
• Authors: Asare, Elliot A.; Davis, Catherine H.; Chiang, Yi‐Ju; Sabir, Sharjeel; Rajkot, Nikita F.; Phillips, Paula R.; Roland, Christina L.; Torres, Keilla E.; Hunt, Kelly K.; Feig, Barry W.
• Is Part Of: Journal of surgical oncology. Volume 121:Issue 3(2020)
• Page Start: 474
• Page End: 479
• Publication Date: 2019-12-17
• Subjects: emergency -- optimize -- outcomes -- rupture -- sarcoma; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.25807
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract: Background: Patients with ruptured, perforated or fistulized (RPF) sarcomas commonly have issues such as sepsis and malnutrition and are usually unsuitable for oncologic resection in the emergency setting. We present our approach for managing a series of patients and the outcomes which were achieved with multidisciplinary care. Methods: We reviewed records of patients referred to the section of sarcoma surgical oncology. Clinicopathologic factors, preoperative and operative interventions as well as short‐term oncologic outcomes were assessed. Results: Sixteen patients were identified between 1 January 1998 to 31 December 2018. Median age was 42.8 years. Histologies were; Gastrointestinal stromal tumors (7), desmoid (4), spindle cell tumor (2), dedifferentiated liposarcoma (2), and nonseminomatous germ cell tumor (1). Five patients had preoperative sepsis, 8 received antimicrobials, and 50% required hospitalization with a median stay of 21 days. Total parenteral nutrition was administered to 5 (31.3%) patients. Median tumor size and estimated blood loss were 13.1 cm and 350 mL respectively. No perioperative mortality occurred. Two patients have expired at a median follow‐up of 16.1 months. Conclusion: Preoperative optimization, including the use of percutaneous drains, and antibiotics to control sepsis, where necessary, can lead to eventual oncologic resection with acceptable morbidity and no short‐term mortality for patients with RPF sarcomas.